Micafungin

Generic Name: Micafungin

Brand Names: Mycamine

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₇₁N_₉O_₂₃S

CAS Number: 235114-32-6

Unique Ingredient Identifier: R10H71BSWG

Background: Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.

Indication: Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been...

Associated Conditions: Abscesses, Aspergillosis, Candidemia, Candidiasis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Acute disseminated Candidiasis

Associated Therapies: -

Clinical Trials

Alternate Day Micafungin: A PK Study in Pediatric Patients

Phase 1

Completed

Conditions: Fungal Infection

Interventions: Drug: Micafungin

First Posted Date: 2009-02-12

Last Posted Date: 2012-02-16

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 15

Registration Number: NCT00842504

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

Phase 4

Completed

Conditions: Candidemia

Interventions: Drug: Micafungin
Drug: Caspofungin

First Posted Date: 2009-02-09

Last Posted Date: 2024-04-30

Lead Sponsor: Gary E. Stein, Pharm.D.

Target Recruit Count: 21

Registration Number: NCT00839540

Locations: 🇺🇸
Sparrow Hospital, Lansing, Michigan, United States

An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates

Phase 1

Completed

Conditions: Candida

Interventions: Drug: Micafungin

First Posted Date: 2009-01-07

Last Posted Date: 2013-03-06

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 13

Registration Number: NCT00818584

Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis

Phase 3

Terminated

Conditions: Candidiasis

Interventions: Drug: amphotericin B deoxycholate
Drug: micafungin

First Posted Date: 2008-12-30

Last Posted Date: 2015-11-04

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 30

Registration Number: NCT00815516

Locations: 🇷🇴
Emergency County Clinical Hospital, Cluj-Napoca, Romania
🇺🇸
WakeMed Health and Hospitals, Raleigh, North Carolina, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 14 locations

Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis

Phase 3

Completed

Conditions: Candidiasis, Oral

Interventions: Drug: Fluconazole
Drug: Micafungin

First Posted Date: 2008-04-24

Last Posted Date: 2014-09-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 523

Registration Number: NCT00666185

Locations: 🇿🇦
2 Sites, Port Elizabeth, South Africa
🇵🇪
4 Sites, Lima, Peru
🇧🇷
8 Sites, Sao Paulo, Brazil

and more 2 locations

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

Phase 3

Completed

Conditions: Candidiasis, Oral

Interventions: Drug: micafungin
Drug: caspofungin

First Posted Date: 2008-04-24

Last Posted Date: 2014-08-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 454

Registration Number: NCT00665639

Locations: 🇧🇷
7 Sites, Sao Paulo, Brazil
🇧🇷
3 Sites, Belo Horizonte, Brazil
🇦🇷
5 Sites, Buenos Aires, Argentina

and more 2 locations

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Phase 1

Completed

Conditions: Oropharyngeal Candidiasis
Candidemia
Invasive Candidiasis
Esophageal Candidiasis

Interventions: Drug: Micafungin

First Posted Date: 2008-02-06

Last Posted Date: 2024-11-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 84

Registration Number: NCT00608335

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
University of California Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
University of Texas Southwestern, Dallas, Texas, United States

and more 10 locations

A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant

Phase 1

Completed

Conditions: Fungal Infections

Interventions: Drug: Micafungin

First Posted Date: 2008-02-01

Last Posted Date: 2014-08-21

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 42

Registration Number: NCT00606268

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis

Phase 4

Withdrawn

Conditions: Aspergillosis/Blood
Aspergillosis/Invasive

First Posted Date: 2007-01-18

Last Posted Date: 2015-09-02

Lead Sponsor: Astellas Pharma Inc

Registration Number: NCT00423163

Micafungin Salvage Mono-therapy in Invasive Aspergillosis

Phase 2

Terminated

Conditions: Invasive Aspergillosis

Interventions: Drug: Systemic antifungal therapy
Drug: Micafungin

First Posted Date: 2006-09-14

Last Posted Date: 2013-09-05

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 17

Registration Number: NCT00376337

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy